Aurinia Pharma
AUPH14.9601.71% ( -0.260 )
Aurinia Pharma (AUPH)
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical nee...
- Open
- 15.240
- High
- 15.381
- Low
- 14.900
- Prev. Close
- 15.220
- Volume
- 1.71M
- Turnover
- 25.71M
- Avg Price
- 15.010
- Bid/Ask Ratio
- --
- Amplitude
- 3.16%
- 52wk High
- 19.250
- Volume Ratio
- 1.90
- Turnover Ratio
- 1.36%
Aurinia Pharma Analyst Rating
View MoreForecast & Rating
Jul 20, 2026Price forecast
$17.0013.64%
Forecast & RatingBuy
7analysts
- Strong buy57.14%
- Buy0.00%
- Hold42.86%
- Sell0.00%
- Strong sell0.00%
News
- Global Report · 18 hours ago
Micro-Cap Liquidity Crunch Contrasts with Semi-Equip Boom in 2026 Mixed Equities Check
- Simplywall · Jul 8 at 02:59 AM
Aurinia Pharmaceuticals (AUPH) Launches PRESERVE Study, Is A 5% Undervalued View Enough?
- Tip Ranks · Jul 6 at 02:35 PM
TD Cowen Reaffirms Their Buy Rating on Aurinia Pharmaceuticals (AUPH)
- PUBT · Jul 6 at 07:15 AM
Aurinia Pharmaceuticals posts corporate presentation on LUPKYNIS growth, autoimmune disease pipeline focus
- PUBT · Jul 6 at 07:01 AM
Aurinia Pharmaceuticals announces press release availability
- Tip Ranks · Jun 12 at 11:34 AM
Aurinia’s PRESERVE Trial: New Combination Strategy for Lupus Nephritis in Focus
